Phase II Study of Consolidation Immunotherapy with Nivolumab and Ipilimumab or Nivolumab alone following Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC): BTCRC-LUN16-081



Study Overview

The purpose of this study is to test the good and bad effects of the study drugs called nivolumab and ipilimumab when given after completing chemotherapy and radiation.


Study Description

The purpose of this study is to test the good and bad effects of the study drugs called nivolumab and ipilimumab when given after completing chemotherapy and radiation.

Additional Information:

Participants will not be paid for their participation.



Research Study Identifier: TX8141
ClinicalTrials.gov Identifier: NCT1707577179 (BTCRC-LUN16-0
Principal Investigator: Greg Durm, MD


Currently Recruiting

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.